Contract and research manufacturer Dishman Pharmaceuticals has got USFDA approval for Active Pharmaceutical Ingredients (API) production at its Naroda facility here.
"The USFDA team has successfully completed the inspection of Dishman's facility situated at Naroda, in Ahmedabad and has approved the facility for API production for the US market," the company said here today.
The Naroda-based facility of Dishman is an Export Oriented Unit (EOU).
Recently, the company had announced to infuse Rs 125 crore by March end this year, and another Rs 125-150 crore next year for opening two new API units, as part of its capex expansion plans.
According to company officials, the group's topline business has been under pressure in the third quarter and the year has been flat so far.
The business coming from our Swiss arm Carbogen Amics went down nearly by 40 per cent, but company order book is robust and outlook for the next fiscal is bright, it added.